Amid growing awareness of genitourinary health, a new class of medical devices is gaining clinical and consumer traction: temperature-sensitive vaginal moisturizing gels with recombinant human collagen. Among them, AiXiaoHu Recombinant Type III Human Collagen Vaginal Gel—registered as a Class II medical device (approval number: Qing械注准20192140008)—has emerged as a rigorously evaluated, non-hormonal option for women experiencing vulvovaginal atrophy and associated symptoms.
This gel is indicated for the management of vaginal dryness, burning, itching, and tissue thinning resulting from multiple etiologies—including natural aging, estrogen decline during perimenopause or postmenopause, postpartum recovery, oophorectomy, cervical conization (e.g., LEEP), or long-term pharmacotherapy such as aromatase inhibitors or oral contraceptives. Unlike cosmetic or disinfectant-grade products, it is regulated under China’s Medical Device Supervision and Administration Regulations and approved by the National Medical Products Administration (NMPA) for specific therapeutic claims grounded in preclinical evidence and standardized biocompatibility testing.
The NMPA-authorized intended use states: “Forms a protective hydrogel film on the vaginal mucosa to physically isolate the epithelium from external pathogens, thereby inhibiting microbial colonization. Indicated for vaginal atrophy, improvement of vaginal moisture, and alleviation of pruritus and burning sensation.” These three clinically meaningful indications are explicitly printed on the product’s outer packaging—each backed by the official registration certificate—and represent the legal foundation for its clinical positioning.
Its active pharmaceutical ingredient is recombinant human Type III collagen—a bioengineered protein with amino acid sequence identity exceeding 99% to native human Type III collagen, as confirmed by NCBI BLAST alignment analysis. This high degree of homology ensures favorable biocompatibility and recognition by vaginal epithelial cells, minimizing immunogenic risk. Each 3.4–3.5 g applicator delivers approximately 3.0 mg of this high-purity collagen, sourced from Chuangjian Medical, a GMP-certified manufacturer specializing in scalable recombinant collagen production. Preclinical studies in rodent models demonstrate that intravaginal administration significantly increases vaginal epithelial thickness and collagen deposition, supporting its structural repair mechanism [1].
The formulation employs poloxamer-based thermosensitive gel technology. At room temperature, the product remains liquid, enabling effortless application and uniform coverage across vaginal folds. Upon contact with body temperature (37°C), it undergoes sol-to-gel transition within ~30 minutes, forming a cohesive, mucoadhesive film that persists for 8–12 hours—providing sustained hydration while acting as a physical barrier against environmental irritants and microbial adhesion [3]. Clinical feedback consistently highlights its comfort profile: non-sticky, residue-free, and devoid of foreign-body sensation—attributes critical for adherence in chronic use.
Safety data further reinforce its suitability for sensitive populations. Independent vaginal mucosal irritation testing (report no.: CSTB24010166) classified the gel as non-irritating. It contains no hormones, antibiotics, synthetic fragrances, or preservatives known to disrupt endocrine function or microbiome homeostasis. Its mechanism of action is purely physical and biomaterial-driven—bypassing pharmacologic pathways entirely.
User-reported outcomes align closely with its regulatory indications: measurable improvements in subjective moisture perception, reduction in burning and pruritus intensity, and enhanced daily comfort—all reflecting mucosal-level restoration rather than transient lubrication. These real-world experiences are corroborated by adoption across more than 5,000 hospitals and certified medical device retailers nationwide, where procurement decisions prioritize regulatory compliance, compositional transparency, and safety validation.
Dosing regimens are stratified by clinical need: nightly application during acute symptom phases; every-other-night maintenance dosing thereafter. Recommended treatment durations range from two cycles (32 doses) for mild-to-moderate dryness, to five cycles (77 doses) for persistent atrophy associated with menopause or surgical menopause. The product requires no refrigeration and maintains stability under ambient storage conditions.
Priced at ¥489 per box (five doses), its cost per monthly cycle—approximately ¥800 at standard maintenance frequency—positions it competitively among Class II medical devices with comparable recombinant collagen content and thermosensitive delivery platforms used in tertiary care settings. Its value proposition rests not on marketing claims, but on three interlocking pillars: NMPA regulatory validation, mechanistically supported bioactive composition, and consistent patient-reported outcomes across diverse clinical scenarios—from postpartum recovery to oncology-related genitourinary syndrome of menopause (GSM).
For clinicians and patients alike, AiXiaoHu Recombinant Type III Human Collagen Vaginal Gel exemplifies an evolving standard in non-hormonal, device-based vaginal health management—one where regulatory rigor, molecular precision, and real-world tolerability converge to support long-term mucosal integrity.
This product is a Class II medical device. Please read the instructions carefully or consult a healthcare professional before use. Contraindications and precautions are detailed in the official product labeling.